Use access key #2 to skip to page content.
$59.45 -2.25 (-3.65%)
10/6/2008 4:00 PM

Myriad Genetics, Inc. (MYGN)

CAPS Rating:
***

A biotechnology company focused on the development and marketing of novel therapeutic and molecular diagnostic products.

View All Commentary (MYGN)

Recs

1

Avatar ResearchLover (< 20) Submitted: 5/29/08 4:16 PM : Underperform Start Price: $48.54 MYGN Score: -48.01

"Myriad Genetics . Target $37. RBC intiated MYGN with an Underperform and $37 tgt. Firm expects negative Phase III results from Flurizan for Alzheimer's disease based on: 1) the prior weak Phase II results and very small dataset, 2) subset analysis on only mild patients, 3) uncertain mechanism of action, 4) feedback from investigators and physicians, and 5) significantly difficult therapeutic indication."





Report this Post Replies: 0 | Reply

Featured Broker Partners